Genus plc (LON:GNS – Get Free Report)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,818.83 ($23.55) and traded as high as GBX 1,970 ($25.50). Genus shares last traded at GBX 1,952 ($25.27), with a volume of 7,896,197 shares.
Analyst Upgrades and Downgrades
Separately, Shore Capital reiterated a “buy” rating on shares of Genus in a research note on Wednesday, December 11th.
Check Out Our Latest Stock Report on GNS
Genus Stock Performance
Genus (LON:GNS – Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) earnings per share (EPS) for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. As a group, research analysts expect that Genus plc will post 70.9644323 EPS for the current fiscal year.
Insider Transactions at Genus
In other news, insider Jorgen Kokke sold 19,967 shares of the firm’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.41), for a total value of £345,628.77 ($447,473.81). 0.75% of the stock is currently owned by corporate insiders.
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
See Also
- Five stocks we like better than Genus
- Basic Materials Stocks Investing
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- The 3 Best Fintech Stocks to Buy Now
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.